Corneal Neovascularization

New blood vessels originating from the corneal veins and extending from the limbus into the adjacent CORNEAL STROMA. Neovascularization in the superficial and/or deep corneal stroma is a sequel to numerous inflammatory diseases of the ocular anterior segment, such as TRACHOMA, viral interstitial KERATITIS, microbial KERATOCONJUNCTIVITIS, and the immune response elicited by CORNEAL TRANSPLANTATION.

Also Known As:

Networked: 838 relevant articles (81 outcomes, 123 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Burns
2.	Chemical Burns (Chemical Burn)
3.	Thrombosis (Thrombus)
4.	Retinopathy of Prematurity (Retrolental Fibroplasia)
5.	Corneal Opacity

Experts

1.	Cursiefen, Claus: 29 articles (09/2014 - 10/2002)
2.	Azar, Dimitri T: 19 articles (08/2015 - 01/2003)
3.	Chang, Jin-Hong: 18 articles (08/2015 - 01/2003)
4.	Bock, Felix: 18 articles (09/2014 - 06/2007)
5.	Chung, Sung Kun: 13 articles (10/2015 - 01/2010)
6.	Dana, Reza: 13 articles (11/2014 - 07/2006)
7.	Ambati, Balamurali K: 12 articles (01/2013 - 08/2002)
8.	Lu, Peirong: 10 articles (09/2015 - 02/2007)
9.	Joo, Choun-Ki: 9 articles (09/2015 - 10/2009)
10.	Kruse, Friedrich E: 9 articles (08/2012 - 04/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Corneal Neovascularization:

1.	bevacizumabFDA Link 01/01/2013 - "Treatment with high-dose topical bevacizumab (25 mg/ml) was effective for corneal neovascularization in nearly two thirds of the eyes treated. " 08/01/2010 - "Topical and subconjunctival bevacizumab application may be useful in the treatment of corneal neovascularization and further study is necessary." 01/01/2014 - "The use of bevacizumab seems to be an effective and safe method in the treatment of corneal neovascularization, either in the subconjunctival or topical application form. " 01/01/2012 - "Both subconjunctival injection and topical use of bevacizumab are effective and safe in controlling corneal neovascularization." 09/01/2009 - "Subconjunctival injection of bevacizumab can partially reduce corneal neovascularization in the short term, and the efficacy of this treatment correlates with the injection dose."
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/01/2002 - "The Miles assay model showed almost complete attenuation of VEGF-mediated vascular leakage following addition of EYE001, and the corneal angiogenesis model also showed a significant reduction in neovascularization with EYE001. " 03/01/2012 - "Anti-VEGF agents are especially effective when administered early, before anatomical changes, such as corneal neovascularization and/or angle closure, are established. " 07/01/2014 - "The aim of the present study was to characterize corneal neovascularization in progressive corneal dystrophy in KLEIP(-/-) mice, to evaluate the efficacy of anti-VEGF therapy, and to identify novel molecular regulators in this experimental model. " 09/01/2012 - "In this study, we demonstrated that UA strongly inhibited in vivo angiogenesis in a chick embryo chorioallantoic membrane assay and vascular endothelial growth factor-induced mouse corneal angiogenesis model. " 07/01/2012 - "Our present study suggests that PEDF-derived synthetic peptide, P5-3 could inhibit the corneal neovascularization induced by chemical cauterization in rats by suppressing VEGF expression via its anti-oxidative properties."
3.	verteporfin (Visudyne)FDA Link 04/01/2012 - "Photodynamic therapy with verteporfin was effective for the treatment of corneal neovascularization in the majority of the cases in this study." 09/01/2007 - "Photodynamic therapy with verteporfin may be effective for the treatment of corneal neovascularization." 09/01/2007 - "To investigate the efficacy of photodynamic therapy with verteporfin for the treatment of patients with corneal neovascularization. " 04/01/2011 - "The aim of this study was to describe the result of photodynamic therapy with verteporfin (Visudyne(®), Novartis Ophthalmics AG, Hettingen, Switzerland) on bilateral corneal neovascularization (CN) and lipid keratopathy. " 04/01/2012 - "Retrospective interventional case series of 33 eyes of 32 patients with stable corneal neovascularization who were refractory to conventional treatment and were treated with single photodynamic therapy with verteporfin (6 mg/m(2)) at King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia between January 1, 2007 and December 30, 2009. "
4.	1-phenyl-3,3-dimethyltriazene (PDT)IBA 03/01/2008 - "PDT with DP-micelle and free DP can provide efficacious treatment of corneal neovascularization." 02/01/2008 - "In an animal model of effects on existing ocular neovascular lesions (corneal neovascularization), PDT monotherapy yielded an initial regression of these vessels, but there followed a rapid regrowth. " 12/01/2012 - "The aim of the present study was to evaluate the change in corneal protein and oxidative stress state after using photodynamic therapy (PDT) for treatment of experimental corneal neovascularization (NV) with benzoporphyrin derivative (BPD). " 07/01/2003 - "In rabbits, PDT of corneal vessels using laser energy of 17 or 50 J/cm(2) resulted in 30% to 50% regression of corneal neovascularization; however, in these animals, a rapid regrowth of new blood vessels occurred between 3 and 5 days. " 01/01/2000 - "We investigated the effect of photodynamic therapy (PDT) using topically administered ATX-S10(Na) on corneal neovascularization (CoNV). "
5.	ranibizumab (Lucentis)FDA Link 06/01/2014 - "To compare the effectiveness of the topical and subconjunctival (SC) ranibizumab treatment in experimental corneal neovascularization (NV) model in rats. " 06/01/2014 - "Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model." 05/01/2014 - "Subconjunctival ranibizumab inhibited corneal neovascularization significantly both in the first and the second week compared to untreated controls (p = 0.006 and p = 0.001, respectively). " 07/01/2013 - "To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV). " 07/01/2013 - "Topical ranibizumab as a treatment of corneal neovascularization."
6.	Ophthalmic Solutions (Eye Drops)IBA 01/01/2011 - "The new eye drops of KH906 may have a broad application for human corneal neovascularization in the near future." 05/01/2009 - "Topical application of mK5 eye drops can prevent corneal graft rejection and corneal neovascularization in rats." 04/01/1998 - "The findings of both investigations showed MMPI eye drops tended to inhibit the corneal neovascularization." 07/01/1989 - "The inhibition of prostaglandin E1-induced corneal neovascularization by steroid eye drops." 08/01/2006 - "RAPA-PGLC DDS and RAPA eye drops can significantly prolong the survival of allografts at high risk and inhibit corneal neovascularization. "
7.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/01/2004 - "In the absence of TNF-alpha, neither Ang-1 nor Ang-2 promoted corneal angiogenesis. " 07/01/2004 - "Systemic overexpression of Ang-1 or Ang-2 dramatically increased corneal angiogenesis induced by TNF-alpha. " 10/01/2015 - "This study investigated the efficacy of topical application of infliximab [tumor necrosis factor-a (TNF-a) monoclonal antibody] in the treatment of corneal neovascularization in the rabbit model. " 02/01/2013 - "To determine the efficacy of topical application of infliximab [tumor necrosis factor-α (TNF-α) monoclonal antibody] for the treatment of corneal neovascularization in the rabbit model. " 06/01/2012 - "We evaluated the roles of tumor necrosis factor (TNF)-α in alkali-induced corneal neovascularization (CNV). "
8.	AngiostatinsIBA 05/15/2007 - "MAb3D5AB1 disrupts tube formation and decreases intracellular pH in endothelial cells exposed to low extracellular pH. Neither angiostatin nor MAb3D5AB1 showed an antiangiogenic effect in the corneal neovascularization assay; however, both were effective in the low-pH environment of the chicken chorioallantoic membrane assay. " 07/01/2012 - "Obtained data shows the promising potential of development of medications based on angiostatin K1-4,5 for suppression of corneal neovascularization and for treatment of diseases associated with corneal ulceration." 01/01/2007 - "The area of corneal neovascularization was significantly lower in eyes injected with rAAV-angiostatin (p<0.01) than in eyes injected with the control virus. " 01/01/2005 - "Because corneal cells generate angiostatins, use of human angiostatins may be a means of treating abnormal corneal neovascularization without the risk of side effects." 08/01/2002 - "This appears to be the first evidence of biologically induced regression of corneal neovascularization, and the first direct demonstration of angiostatin-induced regression of neovascularization in any tissue."
9.	AlkaliesIBA 01/01/2001 - "To study the early events in corneal neovascularization after alkali injury and their relationship to the presence and absence of leukocytes. " 09/01/2015 - "Recently we found high-mobility group box-1 (HMGB1)-Toll-like receptor 4 (TLR4) signaling pathway promotes corneal neovascularization (CNV) induced by alkali in a mouse model. " 09/01/2015 - "High-mobility group box-1-Toll-Like receptor 4 axis mediates the recruitment of endothelial progenitor cells in alkali-induced corneal neovascularization." 07/01/2015 - "Subconjunctivally transplanted, PEDF-transfected ARPE-19 cells secrete rPEDF, which inhibits the corneal neovascularization elicited by alkali cauterization." 01/01/2015 - "Within 72 hours, the transient inflammatory responses in alkali-treated corneas were measured by opacity and corneal neovascularization (CNV) levels, and the gene expression profile of miR-206 was measured by quantitative real-time PCR (qPCR). "
10.	Dexamethasone (Maxidex)FDA LinkGeneric 11/01/2013 - "CsA 0.05% was found to have significantly lesser inhibitory effects on corneal neovascularization than dexamethasone 0.1% (p < 0.001). " 01/01/2013 - "On the 28th day after molding, the corneal neovascularization area of KH902 experimental group was distinctly smaller than that of dexamethasone group, solvent group and saline group (P < 0.05 or P < 0.01). " 09/01/2007 - "Dexamethasone, a synthetic corticosteroid, is widely used as a potent anti-inflammatory drug in various diseases including corneal angiogenesis. " 09/01/2007 - "Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis." 01/01/2012 - "Therefore, dexamethasone completely inhibited the inflammatory corneal angiogenesis with an AR of -0.001 ± 0.006 mm(2)/day, which was significantly lower (p < 0.001) than that observed after treatment with vehicle (0.078 ± 0.024 mm(2)/day) and LASSBio-596 (0.054 ± 0.012 mm(2)/day). "

Therapies and Procedures

1.	Photochemotherapy (Photodynamic Therapy) 10/01/1998 - "Photodynamic therapy appears to be safe and effective for eliciting prolonged (> 28 days) occlusion of corneal neovascularization in the rat model with minimal side effects and good clinical outcomes." 01/01/2013 - "The aim of the present study was to evaluate the effect of photodynamic therapy in the treatment of experimental corneal neovascularization (NV) with benzoporphyrin derivative (BPD). " 12/01/2012 - "Evaluation of protein change and oxidative stress index after photodynamic therapy of corneal neovascularization." 07/01/2012 - "[Research status of photodynamic therapy for corneal neovascularization]." 05/01/2010 - "[Photodynamic therapy with verteporfirin in corneal neovascularization]."
2.	Topical Administration 01/01/2013 - "Topical administration of NPD1 resulted in a significant reduction in the severity and incidence of SK, as well as the extent of corneal neovascularization in the NPD1-treated animals compared to their untreated counterparts. " 01/01/2011 - "The purpose of the current study was to investigate the effect of topical administration of KH906 on corneal neovascularization (NV). " 04/01/2015 - "Topical administration of AuNPs significantly reduced development of inflammatory corneal neovascularization by inhibiting the ERK pathway." 05/01/2014 - "Topical administration of EGCG effectively inhibits corneal neovascularization in rabbits. " 05/01/1982 - "Topical administration of a noncorticosteroidal anti-inflammatory agent may be an effective treatment for corneal neovascularization induced by contact lenses."
3.	Penetrating Keratoplasty 05/01/1989 - "Clinical results in 21 patients with follow-up of 6 months or more have consistently shown improved visual acuity (17 cases), rapid surface healing (19 cases), stable epithelial adhesion without recurrent erosion or persistent epithelial defect (20 cases), arrest or regression of corneal neovascularization (15 cases), and probable increased success for lamellar or penetrating keratoplasty (8 cases). " 01/01/2014 - "Although this technique did not improve visual function, restoring a functional epithelial cell layer and reducing corneal neovascularization provides an improved platform for a penetrating keratoplasty to ultimately improve visual function." 09/01/2014 - "The incidence and degree of corneal neovascularization occurring after penetrating keratoplasty were evaluated in a substudy (LX201-01 study: NCT00447187). " 11/01/1995 - "The purpose of this study was to delineate the patient and surgical factors that contribute to the development of corneal neovascularization (CNV) after penetrating keratoplasty (PK). " 09/01/2014 - "High-dose subconjunctival CsA implants do not significantly affect corneal neovascularization after high-risk penetrating keratoplasty. "
4.	Corneal Transplantation (Keratoplasty) 01/01/2015 - "In the tissue engineering corneal transplantation groups in all three models, the mean number of days to corneal epithelial healing was significantly shorter than that in the control group and the mean number of days to corneal neovascularization was significantly greater than in the control group. " 01/01/1989 - "With up to 4 years follow-up, these cases have consistently demonstrated: (1) improved visual acuity; (2) rapid surface healing; (3) stable epithelial adhesion without recurrent erosion or persistent epithelial defect; (4) consistent regression of corneal neovascularization; (5) restoration of a smooth and optically improved ocular surface; and (6) probably increased success for subsequent keratoplasty." 04/01/2013 - "Eyes with high risk corneal transplantation with corneal neovascularization were included in this interventional study/randomized clinical trial. " 01/01/2015 - "In addition, in the tissue engineering corneal transplantation groups in the central lamellar cornea model and the full-thickness corneal transplantation model neovascularization, corneal turbidity, and epithelial fluorescence were significantly less than in the control groups. " 11/01/2012 - "Postoperative complications after high-risk corneal grafting are decisively associated with corneal neovascularization (CNV). "
5.	Injections 10/01/2014 - "Digital photographs of the eyes were obtained and the surface areas of corneal neovascularization were measured on days 7 and 14 after subconjunctival injections. " 11/01/2010 - "Corneal neovascularization, on average,was 33.70% ± 7.8% (SD) of the total corneal surface before the injections, which decreased to 4.83% ± 3.3% (P = 0.005, t test) at the last follow-up examination. " 11/01/2005 - "Subconjunctival injections of IRS-1 antisense ODN significantly inhibit rat corneal neovascularization. " 05/01/1991 - "However, rats receiving retrobulbar injections exhibited greater corneal neovascularization than those that did not. " 11/01/2010 - "Subconjunctival bevacizumab injections were effective and safe in reducing corneal neovascularization within the first four months. "